The 2016-17 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Adam J. Fein, Ph.D.
Pembroke Consulting, Inc., and Drug Channels Institute

September 2016

Copyright © 2016 by Pembroke Consulting, Inc. All rights reserved.

This report is protected by copyright law and may not be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed, or resold, in whole or in part, in any form or manner or by any means whatsoever, by any person without prior written consent. This report may be cited in commercial documents with full and appropriate attribution. This report is for informational purposes only and is provided “as is” without any express or implied warranty. The analyses in this report are based solely on information and data that are in the public domain. All conclusions, findings, opinions, and recommendations are based on our own experienced and professional judgment and interpretations given the information available. While all information is believed to be reliable at the time of writing, the information provided here is for reference use only and does not constitute the rendering of legal, financial, commercial, or other professional advice by Pembroke Consulting, Inc., Drug Channels Institute, or the author. Any reliance upon the information is at your own risk, and Pembroke Consulting, Inc., and Drug Channels Institute do not make investment recommendations in this report or otherwise. Nothing in this report should be interpreted as an opinion by Pembroke Consulting, Inc., Drug Channels Institute, or the author on the investment prospects of specific companies.

Drug Channels® is a registered trademark of Pembroke Consulting, Inc.
LICENSE TERMS

This report is protected by copyright law. Unauthorized reproduction or distribution of this report or any portion of it may result in severe civil and criminal penalties and will be prosecuted to the maximum extent of the law. This report may be cited in commercial documents with full and appropriate attribution. Nothing in the license is intended to reduce, limit, or restrict any rights arising from fair use under copyright law or other applicable laws.


The complete End User License Agreement is available at:
ABOUT THE AUTHOR

Adam J. Fein, Ph.D., is the president of Pembroke Consulting, Inc., a management advisory and business research firm based in Philadelphia. He also is the CEO of Pembroke’s Drug Channels Institute, a leading management educator for and about the pharmaceutical industry.

Dr. Fein is one of the country’s foremost experts on pharmaceutical economics and the drug distribution system. Top manufacturers call on Dr. Fein’s insights and judgment to create successful commercial strategies and make better strategic decisions in our evolving healthcare environment.

Dr. Fein’s popular and influential Drug Channels website (www.DrugChannels.net) is the go-to source for definitive and comprehensive industry analysis, delivered with a witty edge. He has published hundreds of academic and industry articles, and is regularly quoted in such national publications as *The Wall Street Journal*, *The New York Times*, and many others.

Dr. Fein earned his doctoral degree from the Wharton School of Business at the University of Pennsylvania and a B.A., *summa cum laude*, from Brandeis University. He lives in Philadelphia with his wife, Paula, and their two children.

Contact information
  Adam J. Fein, Ph.D.
  Pembroke Consulting, Inc.
  1515 Market Street, Suite 960
  Philadelphia, PA 19102
  Phone: 215-523-5700
  Website: www.PembrokeConsulting.com
  Email: afein@pembrokeconsulting.com

Visit Dr. Fein’s Drug Channels blog for the latest industry updates!

www.DrugChannels.net
ABOUT DRUG CHANNELS INSTITUTE

Drug Channels Institute (DCI), a division of Pembroke Consulting, Inc., is a leading provider of specialized management education for and about the pharmaceutical industry.

Drug Channels Institute combines Dr. Fein’s expertise and cutting-edge analysis—such as this 2016-17 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors—into comprehensive, interactive e-learning modules that offer your team a thorough grounding in crucial industry topics. These online learning tools explain highly complex economic and business data and concepts so you can:

- Make better decisions to achieve your business goals
- Improve relationships with key accounts
- Understand your customers, channels, and the economics of the U.S. pharmaceutical industry

View a module list at http://drugchannelsinstitute.com/products/e-learning-modules/.

DCI can code and brand any module for your company’s internal Learning Management System. Or you can get started quickly by letting us host your team via our online e-learning portal. DCI’s hosted e-learning modules are instantly viewable on all computer platforms, including iPads.

To learn more about how Drug Channels Institute can help your business, please contact:

Paula Fein, M.S.Ed.
V.P., Business Development
Drug Channels Institute
1515 Market Street, Suite 960
Philadelphia, PA 19102
Phone: 215-523-5700 x11
Website: www.drugchannelsinstitute.com
Email: paula@drugchannelsinstitute.com
INTRODUCTION AND GUIDE TO THIS REPORT

In 2016, pharmaceutical wholesalers face a challenging business environment. Consolidation among pharmacies and providers is accelerating, putting downward pressure on wholesalers’ sell-side margins. Wholesalers are struggling to profit from the specialty pharmacies that dominate the limited networks now favored by manufacturers and third-party payers. The excess profits that wholesalers earned from the generic inflation bubble are vanishing. Payers are targeting provider-administered specialty drugs with new buy-and-bill reimbursement models and novel channel arrangements.

Meanwhile, manufacturers—driven by new regulations and growing gross-to-net discounts offered to third-party payers—are questioning the structure and composition of their payments to wholesalers. Early evidence suggests that the coming wave of biosimilars may be less beneficial to wholesalers than many expected. Yet we project that amid this profit pressure, U.S. drug distribution revenues at the Big Three public wholesalers—AmerisourceBergen, McKesson, and Cardinal Health—will exceed $400 billion in 2016 for the first time ever.

This 2016–17 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors—our seventh edition—will help you understand this turbulent environment. It remains the most comprehensive tool for analyzing the economic and business realities of U.S. pharmaceutical distribution. This unique resource will benefit pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, hospital executives, buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and more.

This report provides an up-to-date, fact-based analysis of the U.S. pharmaceutical wholesale industry and its interactions with—and services for—other participants in our healthcare system. I have synthesized a wealth of statistical data, research studies, financial information, and my own unique business consulting experience into a definitive, nonpartisan resource.

This 2016-17 edition also contains the latest financial data and market positions of the largest public companies: AmerisourceBergen, Cardinal Health, and McKesson. It updates our annual analysis of each wholesaler’s business segments and underlying business profitability, based upon our proprietary economic models. This information allows you to assess differences among the public wholesalers’ business organizations, strategies, and financial performance.

Structure of the 2016-17 Report

This year’s report retains the structure that we introduced with last year’s edition. The 2016-17 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors analyzes the industry in three major sections, comprising nine total chapters. Many sections and chapters have been expanded or reorganized to better cover the latest industry developments. A new Preface section provides an integrated overview of the major themes that recur throughout our analysis. Each theme includes links to relevant chapters and sections within the full report.
Here is a summary of the report’s main sections and chapters.

**SECTION I: WHOLESALER AND CUSTOMER INDUSTRY ANALYSIS**

- **Chapter 1: Industry Overview** (page 1) defines the industry, describes business differences between full-line wholesaling and specialty distribution, explains wholesalers’ channel roles, summarizes wholesalers’ obligations under the Drug Supply Chain Security Act (DSCSA), and identifies the major industry participants and their revenues.

- **Chapter 2: Channel Role for Retail, Mail, and Specialty Pharmacies** (page 22) analyzes the pharmacy market—the customer group that accounts for the majority of wholesalers’ revenues. It covers wholesalers’ services for smaller pharmacies, wholesalers’ participation in the pharmacy-PBM relationship, and their interactions with pharmacy buying groups. The chapter then separately analyzes how wholesalers work with larger pharmacies. An expanded Section 2.4 analyzes wholesalers’ role in the distribution of patient-administered specialty drugs dispensed by specialty pharmacies. We also consider the role of wholesaler-owned specialty pharmacies.

- **Chapter 3: Channel Role for Physician Office/Clinics and Hospitals** (page 49) examines channels for provider-administered medications, explains the buy-and-bill system for drugs administered in outpatient settings, and describes the role and functions that wholesalers perform for hospitals, including hospitals that participate in the 340B Drug Pricing Program. This chapter also provides an in-depth consideration of group purchasing organizations (GPOs) for both hospitals and physician practices. Chapter 3 has been significantly expanded and reorganized from last year’s edition.

**SECTION II: BUSINESS ECONOMICS AND INDUSTRY TRENDS**

- **Chapter 4: Wholesaler Profitability** (page 73) delves into the industry’s income statement economics to explain the underlying sources of drug distribution profits. We deconstruct buy-side and sell-side gross margin components, distinguish sell-side profits from specialty and traditional drugs, and explain distribution service agreements (DSAs) with manufacturers. We analyze overall gross margins and operating profits. This chapter also offers an updated explanation of how brand-name and generic drug price inflation affects profits.

- **Chapter 5: Financial Stability and Cash Management** (page 96) provides a detailed analysis of the key metrics that illustrate wholesalers’ overall financial health, including capital structures, debt (leverage), balance sheet assets, cash flow, return on invested capital, and stock market valuation and performance.

- **Chapter 6: Forces of Change for Drug Distribution** (page 108) analyzes 11 key industry trends that will impact the market structure and economics of the pharmaceutical
wholesaling and specialty distribution industries. Eight of these trends are organized and presented based on wholesalers’ largest customer groups. This chapter has been significantly revised from last year’s edition.

SECTION III: BIG THREE WHOLESALER COMPANY PROFILES

In this section, we analyze the latest financial data and strategies of the largest public companies. Each chapter provides parallel examinations of the Big Three public wholesalers. We scrutinize each company’s business history, acquisitions and divestitures, business mix, profitability, largest customers, and company-specific business trends.

- Chapter 7: AmerisourceBergen Corporation (page 135)
- Chapter 8: Cardinal Health (Page 151)
- Chapter 9: McKesson Corporation (page 163)

How to Use the 2016-17 Report

The chapters are self-contained and do not need to be read in order. We include extensive internal references to help you navigate the entire document and customize it to your specific needs. There are also more than 300 endnotes, most of which have hyperlinks to original source materials.

Please note that highlighted internal references are clickable hyperlinks in the PDF document. After clicking a link, use the following shortcuts to return to your previous location in the document:

- Windows: ALT+Left Arrow
- Mac: Command+Left Arrow

To search the entire PDF document for every occurrence of a word or phrase, use the following keyboard shortcuts:

- Windows: Shift+CTRL+F
- Mac: Shift+Command+F

As always, I welcome your feedback. Please contact me if you have any questions or comments about The 2016-17 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors.

Adam J. Fein
September 2016

P.S. You can find post-publication errata here:
CONTENTS

PREFACE: INDUSTRY TRENDS AND KEY REPORT THEMES ................................................................. 1

SECTION I: WHOLESALER AND CUSTOMER INDUSTRY ANALYSIS .................................................. 5

Chapter 1: Industry Overview ............................................................................................................... 6

1.1. Defining Drug Wholesaling ........................................................................................................ 6

1.1.1. The Products That Wholesalers Sell ....................................................................................... 7

1.1.2. Full-Line Wholesaling ............................................................................................................ 9

1.1.3. Specialty Distribution ............................................................................................................. 11

1.1.4. Regulation and Supply Chain Security .................................................................................... 12

1.2. Overview of Wholesalers’ Channel Role ..................................................................................... 14

1.2.1. Physical Distribution ............................................................................................................. 14

1.2.2. Financial Intermediation ....................................................................................................... 15

1.2.3. Impact on Pharmacy and Provider Reimbursement ............................................................... 16

1.3. Industry Participants ..................................................................................................................... 16

1.3.1. Big Three Wholesalers: Revenues and Growth Trends ......................................................... 16

1.3.2. Other Wholesale Market Participants ................................................................................... 18

1.3.3. Specialty Product Distribution Market Share ........................................................................ 19

Chapter 2: Channel Role for Retail, Mail, and Specialty Pharmacies .................................................. 22

2.1. The Pharmacy Market ................................................................................................................ 22

2.1.1. Outpatient Dispensing Formats .............................................................................................. 22

2.1.2. Differences Among Outpatient Dispensing Formats ............................................................. 23

2.1.3. Pharmacy Market Size and Structure ................................................................................... 25

2.1.4. Recent Changes in Pharmacy Market Structure .................................................................... 26

2.1.5. Wholesale Suppliers to Largest U.S. Pharmacies ................................................................... 26

2.2. Independent Pharmacies ............................................................................................................ 27

2.2.1. Industry Position and Wholesaler Market Shares ................................................................. 28

2.2.2. Wholesaler Services for Independent Pharmacies ............................................................... 30

2.2.3. PSAOs and the Wholesalers’ Role in the Pharmacy-Payer Relationship .................................. 32

2.2.4. Wholesaler Relationships with Pharmacy Buying Groups .................................................. 35

2.2.5. Wholesaler Generic Source Programs for Smaller Pharmacies ........................................... 37

2.3. Retail Chains .............................................................................................................................. 38
Chapter 4: Wholesaler Profitability

SECTION II: BUSINESS ECONOMICS AND INDUSTRY TRENDS

Chapter 3: Channel Role for Physician Offices/Clinics and Hospitals

2.3.1. Brand Distribution Relationships Between Wholesalers and Retail Chains

2.3.2. Generic Sourcing Relationships Between Wholesalers and Large Pharmacies

2.4 Specialty Pharmacies

2.4.1. Specialty Pharmacy Market Participants

2.4.2. Wholesalers’ Specialty Pharmacies

2.4.3. Wholesalers’ Role in Manufacturer-Defined Limited Specialty Networks

Chapter 3: Channel Role for Physician Offices/Clinics and Hospitals

3.1. The Provider-Administered Drug Market

3.1.1. Spending and Sites of Care

3.1.2. The Buy-and-Bill System

3.1.3. Provider Reimbursement in the Buy-and-Bill System

3.1.4. Group Purchasing Organizations (GPOs)

3.1.5. Contract Management and Chargebacks

3.2. Physician Offices

3.2.1. Distributors’ Services for Physician Offices

3.2.2. GPOs for Physician Practices

3.2.3. Physician Dispensing

3.3. Hospitals

3.3.1. Wholesalers’ Services for Hospitals

3.3.2. Hospital GPOs

3.3.3. Specialty Pharmacies at Hospitals and Health Systems

3.3.4. Wholesalers and the 340B Drug Pricing Program

SECTION II: BUSINESS ECONOMICS AND INDUSTRY TRENDS

Chapter 4: Wholesaler Profitability

4.1. Sources of Wholesaler Profits

4.1.1. Gross Profit and Gross Margin

4.1.2. Operating Profit and Operating Margin

4.2. Components of Buy-Side Gross Margin

4.2.1. Distribution Service Agreements

4.2.2. Payment Discounts

4.2.3. Specialty Distribution Service Agreements

4.2.4. Generic Sourcing Formularies
6.2.4. The Outlook for Pharmacy-Dispensed Biosimilars .................................................. 120
6.3. Physician Offices and Hospitals ............................................................................. 122
6.3.1. Hospital Acquisition of Physician Practices and Shifting Sites of Drug Administration .......................................................... 122
6.3.2. Specialty Pharmacy Displacement of Buy-and-Bill Channels ......................... 126
6.3.3. New Buy-and-Bill Reimbursement Models ...................................................... 129
6.3.4. The Impact of Biosimilars Under the Medical Benefit .................................. 131

SECTION III: BIG THREE WHOLESALER PROFILES .................................................. 134

Chapter 7: AmerisourceBergen Corporation ................................................................. 135

7.1. Business Overview .................................................................................................. 135
7.1.1. Company Information ....................................................................................... 135
7.1.2. Company History .............................................................................................. 135
7.1.3. Recent Acquisitions and Divestitures .............................................................. 136
7.1.4. Business Segments ......................................................................................... 137

7.2. Profitability ............................................................................................................. 139
7.2.1. Overall Pharmaceutical Distribution .............................................................. 139
7.2.2. Profitability by Business Sub-Segment ......................................................... 140

7.3. Customers ............................................................................................................... 142
7.3.1. Top 10 Largest Customers .............................................................................. 142
7.3.2. Walgreens Boots Alliance .............................................................................. 143
7.3.3. Express Scripts ................................................................................................. 145

7.4. Growth Trends ...................................................................................................... 146
7.4.1. Distribution Company Growth Trends ............................................................ 147
7.4.2. Specialty Group Trends ................................................................................... 148
7.4.3. MWI Veterinary Supply and Expansion Into Animal Health .................... 149

Chapter 8: Cardinal Health ............................................................................................ 151

8.1. Business Overview .................................................................................................. 151
8.1.1. Company Information ....................................................................................... 151
8.1.2. Company History .............................................................................................. 151
8.1.3. Recent Acquisitions .......................................................................................... 151
8.1.4. Business Segments .......................................................................................... 152

8.2. Profitability ............................................................................................................. 154
8.2.1. Overall Pharmaceutical Distribution .............................................................. 154
LIST OF EXHIBITS

Exhibit 1: Unbranded Generics, Share of U.S. Prescriptions, 2005-2020E .............................................................. 8
Exhibit 2: Full-Line Wholesale Revenues, by Type of Customer, 2014 ................................................................. 10
Exhibit 3: Full-Line Wholesalers, Inventory Levels vs. Product Sales, by Product Type, 2014 .................. 10
Exhibit 4: Specialty Distributor Revenues, by Type of Customer, 2014 ................................................................. 11
Exhibit 5: Specialty Distributor Sales, by Therapeutic Area, 2014 ................................................................. 12
Exhibit 6: Timeline of DSCSA Requirements for Wholesale Distributors, 2013-2023 ................................. 12
Exhibit 7: U.S. Drug Distribution and Related Revenues at Big Three Wholesalers, Calendar Year 2015 .... 17
Exhibit 8: U.S. Revenues and Growth, Big Three Wholesalers, 2012-2016E ...................................................... 17
Exhibit 9: Specialty Product Distribution Revenues, by Division and Parent Company, 2015 .............. 20
Exhibit 10: Average Annual Number of Prescriptions per Pharmacy, by Retail Dispensing Format, 2015 ...... 24
Exhibit 11: Average Annual Prescription Revenue per Retail Pharmacy Outlet, 2015 ................................. 24
Exhibit 12: Total U.S. Pharmacy Industry Revenues, Prescriptions, and Locations, by Dispensing Format, 2015 .......................................................................................................................................................... 25
Exhibit 13: Largest U.S. Pharmacies and Their Primary Wholesale Suppliers, 2016 ................................. 27
Exhibit 14: Number of Independent Pharmacies, 1990-2015 ........................................................................... 28
Exhibit 15: Estimated Drug Sales and Market Share with Independent Pharmacies, by Wholesaler, 2015 ...... 29
Exhibit 16: U.S. Pharmacy Franchise and Marketing Programs of Large Drug Wholesalers, 2016 .......... 30
Exhibit 17: Consumer Satisfaction with Wholesalers’ Pharmacy Group vs. Other Dispensing Formats, 2016 .. 31
Exhibit 18: Wholesaler-Owned Pharmacy Services Administration Organizations, by Members and Ownership, 2016 .................................................................................................................................................. 33
Exhibit 19: Pharmacy Buying Groups and Primary/Preferred Wholesaler Relationships, by Total Purchases, 2016 ........................................................................................................................................... 36
Exhibit 20: Full-Line Wholesaler Sales to Retail Chain Warehouses, 2008 to 2014 ....................................... 38
Exhibit 21: Share of U.S. Generic Purchasing Volume, by Organization, 2016 .................................................... 40
Exhibit 22: Specialty Drug Purchases, by Dispensing Format, 2015 ............................................................. 43
Exhibit 23: Pharmacy Revenues and Market Share from Specialty Pharmaceuticals, by Company, 2015 ...... 44
Exhibit 24: Alternative Channels to Specialty Pharmacies in Limited Networks ............................................. 47
Exhibit 25: Medical Benefit Spending on Provider-Administered Drugs, by Drug Category and Payer, 2014 ... 50
Exhibit 26: Medicare Part B Spending on Provider-Administered Drugs, by Location of Service, 2005-2014 ... 50
Exhibit 27: Commercial Medical Benefit Spending and Claims for Outpatient Provider-Administered Drugs, by Site of Care, 2014 ........................................................................................................................................ 51
Exhibit 28: Buy-and-Bill System for Distribution and Reimbursement of Provider-Administered Outpatient Drugs ................................................................................................................................................. 52
Exhibit 29: Reimbursement Method for Provider-Administered Drugs Paid Under the Commercial Medical Benefit, by Site of Care, 2015 ........................................................................................................ 55
Exhibit 93: McKesson, Distribution Solutions, Gross and Segment Operating Profitability Metrics, 2012-2016
........................................................................................................................................167
Exhibit 94: McKesson, Estimated Revenues and Operating Profit, by Segment, FY 2016......................168
Exhibit 95: McKesson, Top 10 U.S. Drug Distribution Customers, FY2016 ........................................169
Exhibit 96: McKesson, Proforma Revenues from CVS Health, 2011-2016 ........................................171
Exhibit 97: Rite Aid, Days Sales in Inventory, 2013 to 2016 ..............................................................172
Exhibit 99: McKesson Health Mart Store Count, 2006 to 2016 .......................................................174
Exhibit 100: McKesson’s OneStop Generic Program, Revenue Growth Rate, 2010-2016.....................175
Exhibit 101: Celesio, Revenues and Gross Profit, by Operating Segment, 2015 ...............................177
Exhibit 102: Number of Pharmacies, Major European Countries, 2015 ............................................178